DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials by Morgan C, Jin X, Yu X, De Rosa S, Kublin J, Metch B, Keefer M, NIAID H

Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. by Sulo, J, Chimpeni, P, Hatcher, J, Kublin, J, Plowe, C, Molyneux, M, Marsh, K, Taylor, T, Watkins, WM, Winstanley, P

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa by Roux S, Moodie Z, Metch B, Mlisana K, Nchabeleng M, Bekker L, Churchyard G, Gray G, Allen MA, Mathebula M, Bennie T, Kublin J

Lower viral loads and slower CD4 decline in MRKAd5 HIV-1 vaccinees expressing disease-susceptible HLA-B*58:02 by Leitman, E, Hurst, J, Mori, M, Kublin, J, Ndung'u, T, Walker, B, Carlson, J, Gray, G, Matthews, P, Frahm, N, Goulder, P

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study? by Moodie Z, Metch B, Bennie T, Latka M, Mathebula M, Roux S, de Bruyn G, Mlisana K, Nchabeleng M, Churchyard G, Bekker L, Gray GE, Allen M, Eaton N, Kublin J

Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis by Adissu, W, Brito, M, Garbin, E, Macedo, M, Monteiro, W, Mukherjee, SK, Myburg, J, Alam, MS, Bancone, G, Bansil, P, Pal, S, Sharma, A, Zobrist, S, Bryan, A, Chu, CS, Das, S, Domingo, GJ, Hann, A, Kublin, J, Lacerda, MVG, Layton, M, Ley, B, Murphy, SC, Nosten, F, Pereira, D, Price, RN, Talukdar, A, Yilma, D, Gerth-Guyette, E